25,471 Shares in Twist Bioscience Co. (NASDAQ:TWST) Purchased by Simplify Asset Management Inc.

Simplify Asset Management Inc. purchased a new stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 25,471 shares of the company's stock, valued at approximately $1,255,000.

Several other hedge funds have also recently bought and sold shares of the business. American International Group Inc. raised its holdings in Twist Bioscience by 0.8% in the first quarter. American International Group Inc. now owns 28,506 shares of the company's stock valued at $978,000 after buying an additional 213 shares during the period. Caprock Group LLC raised its holdings in Twist Bioscience by 2.9% in the second quarter. Caprock Group LLC now owns 7,851 shares of the company's stock valued at $387,000 after buying an additional 220 shares during the period. Arizona State Retirement System raised its holdings in Twist Bioscience by 1.9% in the second quarter. Arizona State Retirement System now owns 16,187 shares of the company's stock valued at $798,000 after buying an additional 308 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Twist Bioscience by 3.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company's stock valued at $457,000 after purchasing an additional 312 shares during the period. Finally, CWM LLC lifted its position in shares of Twist Bioscience by 27.4% during the second quarter. CWM LLC now owns 2,437 shares of the company's stock worth $120,000 after purchasing an additional 524 shares in the last quarter.

Analysts Set New Price Targets

A number of research firms have recently commented on TWST. Barclays reduced their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, August 5th. Guggenheim began coverage on shares of Twist Bioscience in a research report on Tuesday, June 4th. They set a "buy" rating and a $53.00 target price on the stock. TD Cowen boosted their target price on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a "buy" rating in a research report on Thursday, June 13th. The Goldman Sachs Group boosted their target price on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a "buy" rating in a research report on Tuesday, July 9th. Finally, Robert W. Baird boosted their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an "outperform" rating in a research report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Twist Bioscience currently has an average rating of "Moderate Buy" and a consensus target price of $48.22.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST traded down $1.55 during midday trading on Friday, reaching $46.44. The company had a trading volume of 1,409,324 shares, compared to its average volume of 1,007,369. The stock's fifty day moving average price is $47.41 and its 200-day moving average price is $42.95. The stock has a market capitalization of $2.72 billion, a P/E ratio of -14.28 and a beta of 1.76. Twist Bioscience Co. has a one year low of $14.42 and a one year high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The company had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. During the same quarter last year, the firm posted ($1.01) EPS. The firm's quarterly revenue was up 27.7% on a year-over-year basis. As a group, sell-side analysts forecast that Twist Bioscience Co. will post -3.13 earnings per share for the current year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 1,137 shares of the business's stock in a transaction on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $45,400.41. Following the completion of the sale, the senior vice president now owns 88,837 shares in the company, valued at $3,547,261.41. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, SVP Paula Green sold 1,137 shares of the company's stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $45,400.41. Following the completion of the transaction, the senior vice president now owns 88,837 shares in the company, valued at $3,547,261.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Emily M. Leproust sold 1,114 shares of the company's stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $48.00, for a total transaction of $53,472.00. Following the transaction, the chief executive officer now owns 504,732 shares of the company's stock, valued at approximately $24,227,136. The disclosure for this sale can be found here. Insiders sold a total of 15,125 shares of company stock worth $664,784 over the last 90 days. Insiders own 3.92% of the company's stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.